Study of Endoscopic Ultrasound-guided Radiofrequency Ablation for Pancreatic and Adrenal Tumors to Assess Long-Term Effectiveness and Patient Quality of Life

What this Trial Is About

Researchers are evaluating the long-term effects of Endoscopic Ultrasound-guided Radiofrequency Ablation EUS-RFA in patients with pancreatic or adrenal tumors. This observational study aims to measure clinical improvement in symptoms and biochemical markers, as well as patient satisfaction and quality of life. It also looks at the safety and technical success of the procedure and explores factors linked to outcomes. The study is sponsored by Herlev Hospital and includes patients with benign or small hormone-producing tumors such as insulinomas and Conn syndrome. Participants will receive EUS-RFA as part of their standard care. During the procedure, a fine needle guided by an endoscope and ultrasound delivers radiofrequency energy to heat and destroy tumor cells while sparing nearby tissues. Follow-up includes regular blood tests, imaging scans, and clinical assessments for up to 5 years after treatment. Participants will also complete questionnaires about their satisfaction and quality of life related to their condition. Throughout the study, researchers will monitor clinical effectiveness, patient satisfaction, adverse events, and technical success rates. Data collection will continue until 2040 to assess long-term outcomes, with about 138 patients enrolled between 2025 and 2035. The goal is to determine if EUS-RFA can safely and effectively replace traditional surgery for selected patients, potentially lowering surgical risks and improving recovery and quality of life.

Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions